Trinity Biotech (TRIB) EBITDA Margin (2009 - 2024)
Trinity Biotech recorded quarterly EBITDA Margin of 72.61% in Q4 2024, down 330.07% quarter-over-quarter from 16.88% in Q3 2024, and down 4446.0% year-over-year from 1.67% in Q1 2024.
Trinity Biotech's EBITDA Margin history runs 16 years deep, the most recent figure standing at 72.61% for Q4 2024.
- In Q4 2024, EBITDA Margin fell 4446.0% year-over-year to 72.61%; the TTM figure through Dec 2024 stood at 34.38% (up 1321.0% YoY), while the FY2025 annual figure was 36.06%, down 168.0% from the prior year.
- EBITDA Margin came in at 72.61% for Q4 2024 at Trinity Biotech, down from 16.88% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 28.38% in Q3 2020 to a low of 106.86% in Q2 2023.
- A 5-year average of 17.79% and a median of 14.44% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 9486 bps in 2023 and soared 8129 bps in 2024, its largest moves.
- Trinity Biotech's EBITDA Margin stood at 27.67% in 2020, then slumped by 90 bps to 2.88% in 2021, then sank by 1899 bps to 51.87% in 2022, then surged by 46 bps to 28.14% in 2023, then plunged by 158 bps to 72.61% in 2024.
- According to Business Quant data, EBITDA Margin over the past three periods registered 72.61%, 16.88%, and 25.58% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Trinity Biotech | 28,000.00 | -5.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -72.61% |
| Sep 30, 2024 | -16.88% |
| Jun 30, 2024 | -25.58% |
| Mar 31, 2024 | -20.68% |
| Dec 31, 2023 | -28.14% |
| Sep 30, 2023 | -30.66% |
| Jun 30, 2023 | -106.86% |
| Mar 31, 2023 | -26.43% |
| Dec 31, 2022 | -51.87% |
| Sep 30, 2022 | -51.78% |
| Jun 30, 2022 | -12.00% |
| Mar 31, 2022 | -7.76% |
| Dec 31, 2021 | 2.88% |
| Sep 30, 2021 | 12.58% |
| Jun 30, 2021 | 0.84% |
| Mar 31, 2021 | 12.03% |
| Dec 31, 2020 | 27.67% |
| Sep 30, 2020 | 28.38% |
| Jun 30, 2020 | 3.13% |
| Mar 31, 2020 | 7.99% |
| Dec 31, 2019 | 6.77% |
| Sep 30, 2019 | 5.42% |
| Jun 30, 2019 | 5.36% |
| Mar 31, 2019 | 5.99% |
| Dec 31, 2018 | 7.82% |
| Sep 30, 2018 | 5.21% |
| Jun 30, 2018 | 6.90% |
| Mar 31, 2018 | 7.59% |
| Dec 31, 2017 | 3.30% |
| Sep 30, 2017 | 5.97% |
| Jun 30, 2017 | 7.20% |
| Mar 31, 2017 | 5.56% |
| Dec 31, 2016 | 2.50% |
| Sep 30, 2016 | 10.40% |
| Jun 30, 2016 | 8.96% |
| Mar 31, 2016 | 7.76% |
| Dec 31, 2015 | 12.56% |
| Sep 30, 2015 | 11.53% |
| Jun 30, 2015 | 12.41% |
| Mar 31, 2015 | 17.18% |
| Dec 31, 2014 | 16.11% |
| Sep 30, 2014 | 17.09% |
| Jun 30, 2014 | 17.66% |
| Mar 31, 2014 | 18.00% |
| Dec 31, 2013 | 19.00% |
| Sep 30, 2013 | 19.85% |
| Jun 30, 2013 | 17.20% |
| Mar 31, 2013 | 19.14% |
| Dec 31, 2012 | 21.08% |
| Sep 30, 2012 | 20.86% |
| Jun 30, 2012 | 20.64% |
| Mar 31, 2012 | 20.63% |
| Dec 31, 2011 | 20.47% |
| Sep 30, 2011 | 20.68% |
| Jun 30, 2011 | 19.98% |
| Mar 31, 2011 | 19.83% |
| Dec 31, 2010 | 18.58% |
| Sep 30, 2010 | 17.42% |
| Jun 30, 2010 | 15.51% |
| Mar 31, 2010 | 12.67% |
| Dec 31, 2009 | 11.32% |
| Sep 30, 2009 | 11.77% |
| Jun 30, 2009 | 11.89% |
| Mar 31, 2009 | 9.78% |